The small molecule TH5487 safely and effectively treated pulmonary fibrosis (PF) in a mouse model, a study reported. Although TH5487 is known to block the activity of the DNA repair enzyme OGG1, its anti-fibrotic effects occurred, in part, by reducing the production of OGG1 itself. According to researchers, these…
News
The Pulmonary Fibrosis Foundation’s PFF Care Center Network (CCN) now includes 74 medical centers in 34 U.S. states, after six more sites specializing in pulmonary fibrosis (PF) diagnosis, treatment, and patient support joined the nationwide program. “Our new PFF Care Center Network sites offer much-needed comprehensive care for…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to EI-1071, an oral anti-inflammatory that Elixiron Immunotherapeutics is developing for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug status is awarded by the FDA to therapies designed to improve medical care for rare disorders —…
Algernon Pharmaceuticals’ experimental oral therapy NP-120 (ifenprodil) significantly reduced coughing in people with idiopathic pulmonary fibrosis (IPF), according to a new analysis of top-line data from a proof-of-concept Phase 2a clinical trial. The analysis showed the therapy was much more effective at easing cough than previously reported. NP-120’s “potential…
A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases have been selected to receive a Horizon Therapeutics‘ #RAREis Global Advocate Grant. Winners of this year’s inaugural awards are spread across nine countries and represent a total of 29 rare…
The U.S. Food and Drug Administration (FDA) has given fast-track designation to DWN12088, an experimental anti-fibrotic medication that Daewoong Pharmaceutical is developing to treat idiopathic pulmonary fibrosis (IPF). Fast track designation is given to therapies that are intended to treat serious conditions and fill an unmet medical need.
Most idiopathic pulmonary fibrosis (IPF) patients treated with NP-120 (ifenprodil) in a 12-week clinical trial saw their lung function improve or stabilize, and most also experienced an easing in coughing, according to top-line data announced by the therapy’s developer, Algernon Pharmaceuticals. “Simply put, the IPF data is better than we…
The Pulmonary Fibrosis Foundation (PFF) is hosting its sixth annual PFF Walk fundraiser with virtual and in-person events over the next few months to raise funds and awareness in support of people living with pulmonary fibrosis. “We encourage everyone to join us in celebrating these individuals and helping…
Nonprofits, scientists, governmental organizations, and the rare disease drug development industry have long cited 7,000 as the average number of rare diseases in the world. But a new analysis shows there are as many as 10,867 rare diseases globally. And that…
The experimental oral therapy PLN-74809 was overall well tolerated in people with idiopathic pulmonary fibrosis (IPF) participating in the Phase 2a INTEGRIS-IPF trial, according to new data announced by its developer, Pliant Therapeutics. The data also indicated that PLN-74809 was able to slow lung function decline when given…
